Simon et al reviewed the skeletal consequences of discontinuing HT and the specific treatment options for these women. [12] This analysis included 11 RCTs that reported data on BMD changes during and ...

Long-term treatment with a bisphosphonate degrades fracture-resistance–toughening mechanisms that contribute to healthy bone, setting the stage for the rare but catastrophic risk of patients ...

The FDA analyses looked at a composite end point of all fractures, both vertebral and nonvertebral, and showed little benefit of continued bisphosphonate treatment beyond 5 years. The original ...

Studies show conflicting results regarding the possible excess risk of atypical fractures of the femoral shaft associated with bisphosphonate use. In Sweden, 12,777 women 55 years of age or older ...

Please provide your email address to receive an email when new articles are posted on . Among South-East Asian adults, bisphosphonate use in is not associated with differences in clinical outcomes or ...

Development of an Actionable Framework to Address Cancer Care Disparities in Medically Underserved Populations in the United States: Expert Roundtable Recommendations We conducted a retrospective ...

Directing Surgical Quality Improvement Initiatives: Comparison of Perioperative Mortality and Long-Term Survival for Cancer Surgery Osteonecrosis of the jaws (ONJ) was initially described in 2001 in ...

Bisphosphonates are a class of drugs that reduce the rate of bone turnover. Osteochemonecrosis is a drug-induced condition in which part of the jawbone dies and cannot regenerate due to lack of blood ...

Bones are living tissues that undergo constant remodelling. In a healthy bone that has finished growing, the breakdown of old bone (by osteoclasts) and the formation of new bone (by osteoblasts) is a ...

Osteoporosis is underrecognized and undertreated despite the availability of effective therapies that reduce fracture risks. Bisphosphonates are currently the most widely prescribed pharmacologic ...